Actualités Satellos Bioscience Inc - MSCL | Actions Toronto Stock Exchange

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Satellos Reports 2025 Financial Results and Highlights Recent Company Progress

Completed a US$57.2 million equity financing; commenced trading on the Nasdaq Global Market under the ticker...

Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall...

Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing...

Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy

Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing...

Satellos to Participate in Upcoming Investor Conferences

Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company focused on restoring...

Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy

BASECAMP, a three-month, randomized, double-blind, placebo-controlled study, will evaluate SAT-3247’s safety and tolerability, and effect on...

Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company focused on restoring...

Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares

Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Satellos Bioscience Inc (MSCL)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Satellos Bioscience Inc (MSCL) Actualités

Satellos Reports 2025 Financial Results and Highlights Recent Company Progress

Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy

Satellos to Participate in Upcoming Investor Conferences

Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy

Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares

L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - MSCL

Canadian Investment Regulatory Organization Trade Resumption - MSCL

Suspension de la négociation par l'Organisme canadien de réglementation des investissements - MSCL

Canadian Investment Regulatory Organization Trading Halt - MSCL

Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States

Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq

Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Satellos Bioscience Inc (MSCL)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Satellos Bioscience Inc (MSCL) Actualités

Satellos Reports 2025 Financial Results and Highlights Recent Company Progress

Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy

Satellos to Participate in Upcoming Investor Conferences

Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy

Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares

L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - MSCL

Canadian Investment Regulatory Organization Trade Resumption - MSCL

Suspension de la négociation par l'Organisme canadien de réglementation des investissements - MSCL

Canadian Investment Regulatory Organization Trading Halt - MSCL

Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States

Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq

Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités